Aspartame is an artificial non-saccharide sweetener commonly used as a sugar substitute in foods and beverages. 200 times sweeter than sucrose, it is a methyl ester of the aspartic acid/phenylalanine dipeptide with brand names NutraSweet, Equal, and Canderel. Discovered in 1965, aspartame was approved by the US Food and Drug Administration (FDA) in 1974 and re-approved in 1981 after its initial approval was briefly revoked.
Aspartame is one of the most studied food additives in the human food supply. Reviews by over 100 governmental regulatory bodies found the ingredient safe for consumption at the normal acceptable daily intake limit. |
Read full article at Wikipedia
|
InChI=1S/C12H20N2O3S/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17/h4-7,9,12-15H,8H2,1-3H3 |
ZBMZVLHSJCTVON-UHFFFAOYSA-N |
CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1 |
|
environmental contaminant
Any minor or unwanted substance introduced into the environment that can have undesired effects.
Bronsted base
A molecular entity capable of accepting a hydron from a donor (Bronsted acid).
(via organic amino compound )
|
|
xenobiotic
A xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
beta-adrenergic antagonist
An agent that binds to but does not activate beta-adrenergic receptors thereby blocking the actions of endogenous or exogenous beta-adrenergic agonists. beta-Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches and anxiety.
|
|
beta-adrenergic antagonist
An agent that binds to but does not activate beta-adrenergic receptors thereby blocking the actions of endogenous or exogenous beta-adrenergic agonists. beta-Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches and anxiety.
anti-arrhythmia drug
A drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres.
|
|
View more via ChEBI Ontology
N-{4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl}methanesulfonamide
|
sotalol
|
ChemIDplus
|
sotalolum
|
ChemIDplus
|
4'-(1-hydroxy-2-(isopropylamino)ethyl)methane sulfonanilide
|
ChemIDplus
|
β-cardone
|
ChemIDplus
|
Sotalol
|
KEGG COMPOUND
|
2464
|
DrugCentral
|
C07309
|
KEGG COMPOUND
|
D08525
|
KEGG DRUG
|
DB00489
|
DrugBank
|
HMDB0014632
|
HMDB
|
LSM-1465
|
LINCS
|
Sotalol
|
Wikipedia
|
View more database links |
2380820
|
Reaxys Registry Number
|
Reaxys
|
3930-20-9
|
CAS Registry Number
|
KEGG COMPOUND
|
3930-20-9
|
CAS Registry Number
|
ChemIDplus
|
20562595
|
PubMed citation
|
Europe PMC
|
21553267
|
PubMed citation
|
Europe PMC
|
21854895
|
PubMed citation
|
Europe PMC
|
|